about
A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosisIdentification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphismsSearch for specific biomarkers of IFNβ bioactivity in patients with multiple sclerosis.Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis.Baseline gene expression signatures in monocytes from multiple sclerosis patients treated with interferon-betaRisk acceptance in multiple sclerosis patients on natalizumab treatment.NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis.Pharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN-β.Interferon-beta 1b in the treatment of multiple sclerosis.Neurofilament light chain level is a weak risk factor for the development of MS.Multiple sclerosis: current treatment algorithms.Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis.MR Imaging in Monitoring and Predicting Treatment Response in Multiple Sclerosis.Assessing response to interferon-β in a multicenter dataset of patients with MS.Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab.Baseline MRI predicts future attacks and disability in clinically isolated syndromes.Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis.Defining high, medium and low impact prognostic factors for developing multiple sclerosis.Predictive value of early brain atrophy on response in patients treated with interferon βA 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.Up-regulation of inducible heat shock protein-70 expression in multiple sclerosis patients.Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.Interferon beta in secondary progressive multiple sclerosis : daily clinical practice.Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis.Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis.Serial gadolinium-enhanced MRI in acute attack of multiple sclerosis treated with plasma exchange.Roles of the ubiquitin peptidase USP18 in multiple sclerosis and the response to interferon-β treatment.Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months.Plasma osteopontin levels in multiple sclerosis.HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis.Scoring treatment response in patients with relapsing multiple sclerosis.Plasma chitotriosidase activity in multiple sclerosis.Do multimodal evoked potentials add information to MRI in clinically isolated syndromes?The basal ganglia: a substrate for fatigue in multiple sclerosis.Lesion topographies in multiple sclerosis diagnosis: A reappraisal.Unconventional therapy in multiple sclerosis.Polyregional and hemispheric syndromes: a study of these uncommon first attacks in a CIS cohort.Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes.Correction to: Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.
P50
Q28257957-C107FA1C-635A-4355-89C9-22D0FD10122BQ33378475-906739B0-B575-46BB-8DD2-0A4D823F2E70Q34008878-A34356A8-9A08-435D-B34C-A9DC1D953DA8Q34550413-369F6C3B-C89F-4684-BED9-BDC277D9B3A4Q34700070-8725349B-7B30-4120-85A1-B643EA6DC846Q35067882-BA871160-4EB4-4C9C-BC88-1878E964984BQ35533948-34C13702-DE83-4150-9829-86789E82C903Q36092690-37ADE8CD-184E-4B46-8269-FCF0E1179552Q36327113-3218C535-FE1C-4079-BEC9-3ABCF06672C9Q37265143-15C6CF47-BA80-422F-A3C9-C38EDB03642FQ37866036-FD3150D8-C6DF-4AD2-83E1-5C48C516BAF8Q38298159-1D378C97-F7C9-411C-8536-8F5B87C18361Q38711659-862567A2-473E-4FCB-96DD-AB2A7474AF3DQ38732917-1E9A7DCE-4297-4001-9A1E-B7E8C2A2A1F8Q39680742-38FAAE23-0BD3-4C2F-887B-A0CC92AE2EAEQ40160845-B0B15496-C08C-4D8D-B64C-3EE574F29971Q40285067-8A137B5A-F906-4639-9C6A-F3CD55BC30EAQ40413987-3674A4A5-D061-4590-BD16-7B0DDF826B43Q41029094-0218EDC5-E5D8-423D-989A-B311C2AAD660Q41197913-6BD515DB-8BD4-4D55-BEE4-ABAE41B62CB4Q41369774-FA139AF0-722C-4473-8A8E-9CC9A2F73EC2Q42450783-746D4BD2-84E3-48EB-AED4-853E014D338AQ42516732-0E598872-A02C-44BF-93AF-ED44A3F9D1A1Q42614620-779FFC4F-C18C-42F3-A861-667C2C37FA59Q42695938-BE9B1209-CB04-4290-8792-E55714CA71F5Q43295138-39E4C16E-2A08-4D76-953C-D6C77F20B5DEQ44351938-59061258-6664-46E4-9364-2A20EFF0D97AQ44563293-C960CF1D-7AC9-42F8-A422-02230AAC4A2CQ44834486-6CA75963-CE9E-48B8-97F4-9C9701EF1163Q45180843-4D2EFAC0-E481-44C4-8249-1263A6B01395Q45801403-8D7F7619-F8E7-49E2-918A-650B02562388Q46220687-56DB9E7C-ED3D-43B4-A815-A114D3F0A2F2Q46250626-416AAF7E-1FA7-4412-A4DF-4C98C451CDE3Q46823548-A481FFC7-9213-467F-ACF2-BD205AC89556Q46936365-E9BD024F-EFA1-462E-B412-14AAFB2369DFQ47138738-57EA2D55-B44C-4B20-BF28-68C4A5C3779FQ47821282-A2842FCF-AA4D-4B02-84B8-92A75E639439Q48114435-1039FE79-6FAF-413A-85D7-DD693363C42EQ48210503-A45C1EBD-6A75-422F-A123-1865E6475DB4Q48234976-FF2D3827-9782-460A-BF8F-F025E85860AA
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jordi Rio
@ast
Jordi Rio
@en
Jordi Rio
@es
Jordi Rio
@nl
type
label
Jordi Rio
@ast
Jordi Rio
@en
Jordi Rio
@es
Jordi Rio
@nl
prefLabel
Jordi Rio
@ast
Jordi Rio
@en
Jordi Rio
@es
Jordi Rio
@nl
P106
P1153
7006734684
P21
P31
P496
0000-0003-4546-7627